We set out to determine which characteristics and outcomes of stroke are associated with COVID-19. Methods This case-control study included patients admitted with stroke to 13 hospitals in England and Scotland between 9 th March and 5 th July 2020. We collected data on86strokes (81 ischaemic strokes and 5intracerebral haemorrhages)in patients withevidence of COVID-19 at the time of stroke onset (Cases). They were compared with 1384strokes(1193 ischaemic strokes and 191 intracerebral haemorrhages) in patients admitted during the same time periodwho never had evidence of COVID-19 (Controls). In addition the whole group of stroke admissions, including another 37 in patients who appear to have developed COVID-19 after their stroke, were included in two logistic regression analyses examining which features wereindependently associated with COVID-19 status and with inpatient mortality. Results Cases with ischaemic stroke were more likely than ischaemic controls to occur in Asians (18.8% vs 6.7%, p<0.0002), were more likely to involve multiple large vessel occlusions (17•9% vs 8.1%, p<0•03), were more severe (median NIHSS 8 vs 5, p<0•002), were associated with higher D-dimer levels (p<0•01) and were associated withmore severe disability on discharge (median mRS 4 vs 3, p<0•0001) and inpatientdeath (19.8% vs9•6%, p<0•0001). Recurrence of stroke during the patient's admission was rare in Cases and Controls (2.3% vs1.0%, NS). Conclusions Our data suggest that COVID-19 may be an important modifier of the onset, characteristics and outcome of acute ischaemic stroke.

The benefits of CPAP demonstrated in clinical trials are difficult to deliver in real life due to the lack of adherence. We analysed the effect of a Telemonitoring (TM)-related intervention on adherence as part of a Service Improvement Project (SIP) analysed as a retrospective cohort study. The ‘historical control’ (HC) cohort (followed up in conventional clinics) included all patients who commenced on CPAP between 1 February and 30 April 2019 (n = 142). The ‘telemonitoring’ (TM) cohort included all patients who commenced on CPAP between 1 May and 31 July 2019 (n = 166). Adherence was checked at 30 days (baseline) and 73 days for both cohorts. Wilcoxon—Rank test was used for statistical analysis (results reported as mean ± SEM). Both cohorts had similar adherence at the 30-day baseline, compared to a significantly lower adherence in the HC-cohort at 73 days (55.7 ± 3.0 vs. 51.8 ± 3.2% of days ≥ 4 h: p = 0.0072, average usage 255 ± 12.8 vs. 236 ± 13.7 min: p = 0.0003). There was a significantly higher adherence in the TM-cohort at 73 days (50.8 ± 2.5 vs. 56.1 ± 2.9% of days ≥ 4 h: p = 0.0075; average usage 234 ± 10.4 vs. 252 ± 12.1 min: p = 0.0456). Telemonitoring-feedback is effective at improving adherence with CPAP, suggesting its potential beneficial role in the community setting, particularly in the post-COVID reality of increased remote consultations.

No abstract

No abstract

No abstract